1. Home
  2. CAN vs SKYE Comparison

CAN vs SKYE Comparison

Compare CAN & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAN
  • SKYE
  • Stock Information
  • Founded
  • CAN 2013
  • SKYE 2012
  • Country
  • CAN China
  • SKYE United States
  • Employees
  • CAN N/A
  • SKYE N/A
  • Industry
  • CAN Semiconductors
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • CAN Technology
  • SKYE Health Care
  • Exchange
  • CAN Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • CAN 291.8M
  • SKYE 294.2M
  • IPO Year
  • CAN 2019
  • SKYE N/A
  • Fundamental
  • Price
  • CAN $1.07
  • SKYE $6.44
  • Analyst Decision
  • CAN Strong Buy
  • SKYE Strong Buy
  • Analyst Count
  • CAN 2
  • SKYE 4
  • Target Price
  • CAN $4.25
  • SKYE $19.25
  • AVG Volume (30 Days)
  • CAN 6.3M
  • SKYE 414.1K
  • Earning Date
  • CAN 08-27-2024
  • SKYE 01-01-0001
  • Dividend Yield
  • CAN N/A
  • SKYE N/A
  • EPS Growth
  • CAN N/A
  • SKYE N/A
  • EPS
  • CAN N/A
  • SKYE N/A
  • Revenue
  • CAN $191,336,000.00
  • SKYE N/A
  • Revenue This Year
  • CAN $7.46
  • SKYE N/A
  • Revenue Next Year
  • CAN N/A
  • SKYE N/A
  • P/E Ratio
  • CAN N/A
  • SKYE N/A
  • Revenue Growth
  • CAN N/A
  • SKYE N/A
  • 52 Week Low
  • CAN $0.75
  • SKYE $1.44
  • 52 Week High
  • CAN $3.50
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • CAN 53.17
  • SKYE 36.20
  • Support Level
  • CAN $1.00
  • SKYE $5.48
  • Resistance Level
  • CAN $1.12
  • SKYE $6.93
  • Average True Range (ATR)
  • CAN 0.07
  • SKYE 1.03
  • MACD
  • CAN 0.00
  • SKYE -0.03
  • Stochastic Oscillator
  • CAN 59.60
  • SKYE 37.30

About CAN Canaan Inc.

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: